Semaglutide (Wegovy, Ozempic), liraglutide (Saxenda, Victoza), tirzepatide (Zepbound, Mounjaro)
Research from Universit de Louvain demonstrated that Akkermansia interacts with L-cells to enhance GLP-1 secretion (PMID: 33820962)
Signaling a feeling of fullness
For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
Common side effects include nausea, bloating, constipation, or upset stomachespecially as your dose increases
Its not about deprivation